The NICOTINURSE Trial: Protocol for a stepped-wedge trial to implement nurse-led smoking cessation support in a tertiary care hospital.
4 affiliations
- 1Centre ambulatoire d'addictologie, Hôpital Européen Georges Pompidou, Paris, France.
- 2Clinical Research Unit, Georges Pompidou European Hospital, AP-HP Centre - Paris Cité University, Paris, France.
- 3Vascular Medicine/Hypertension Department, Georges Pompidou European Hospital, AP-HP Centre-Paris Cité University, Paris, France.
- 4Centre Ambulatoire d'Addictologie, AP-HP Centre - Université Paris Cité, Paris, France.
Abstract
Smoking cessation support is still lacking during hospital stay, leading smokers to suffer from withdrawal symptoms and missing opportunities to help them quit. In this context, NICOTINURSE is a stepped-wedge cluster randomized trial aimed to evaluate the effectiveness of a nurse-led support and nicotine replacement therapy (NRT) prescription during smokers' hospital stay in four departments of a university hospital on one-month abstinence after discharge with a follow-up of quit attempts at 3 and 6 months. This is a stepped-wedge cluster trial, including four hospital departments. Inpatients who smoke in the experimental group will receive structured counseling and NRT prescribed by trained nurses in smoking cessation before discharge, while smokers in the control group receive standard care. The primary outcome is one-month abstinence post-discharge confirmed biochemically. Secondary outcomes, assessed at 1, 3, and 6 months post-discharge, include: abstinence, mean number of cigarettes smoked daily, quality of life scale, anxiety and depression symptoms score, addiction center use, and prescribed NRT during hospitalization and at discharge. Nurse job satisfaction will be measured at the beginning and at the end of the study. Statistical analyses will compare intervention and control groups using models appropriate for the stepped-wedge cluster randomized design (two-sided α = 0.05). Based on an expected 1-month abstinence rate of 15% in the control group and 30% in the intervention group, with 80% power, an intraclass correlation coefficient of 0.30, and 5% loss to follow-up, a total sample size of 442 participants is required. All data collected about the study participants will be anonymized. Results will be communicated to participants, hospital departments' staff and other relevant groups without any restrictions. The study is registered on the official website of ClinicalTrials.gov. NCT06789536.
Related
- Study protocol for the Collaborative Registrar Education and Training Enhancement (CREATE) project: a mixed-methods participatory study to co-design, implement and evaluate innovations to optimise GP training.
- A pilot study to implement artificial intelligence-enabled, point-of-care obstetric ultrasound for gestational age estimation in Zambia: An evaluation protocol
- Actívatexto: Advancing Smoking Cessation and Physical Activity among Latino Adults. Study Protocol for a Randomized Clinical Trial
- A Randomized Factorial Trial of Varenicline, Nicotine Lozenges, and Smartphone Medication Adherence Reminders for Smoking Cessation: Protocol for the COMBO II Study.
- Mapping the adoption and implementation of artificial intelligence (AI)-based conversational interface for tobacco cessation: a scoping review protocol.
BibTeX
@article{savundrarajan2026nicotinurse,
title = {{The NICOTINURSE Trial: Protocol for a stepped-wedge trial to implement nurse-led smoking cessation support in a tertiary care hospital.}},
author = {Anusha Savundrarajan and Anne-Isabelle Tropeano and Aurelie Vilfaillot and Marie-Laure Delaporte and Anne-Laurence Le Faou},
journal = {Tobacco induced diseases},
year = {2026},
month = oct,
doi = {10.18332/tid/231136},
url = {https://europepmc.org/article/MED/42997245},
note = {CC BY},
}
RIS
TY - JOUR
TI - The NICOTINURSE Trial: Protocol for a stepped-wedge trial to implement nurse-led smoking cessation support in a tertiary care hospital.
AU - Anusha Savundrarajan
AU - Anne-Isabelle Tropeano
AU - Aurelie Vilfaillot
AU - Marie-Laure Delaporte
AU - Anne-Laurence Le Faou
PY - 2026
DA - 2026/10/31
JO - Tobacco induced diseases
DO - 10.18332/tid/231136
UR - https://europepmc.org/article/MED/42997245
AB - Smoking cessation support is still lacking during hospital stay, leading smokers to suffer from withdrawal symptoms and missing opportunities to help them quit. In this context, NICOTINURSE is a stepped-wedge cluster randomized trial aimed to evaluate the effectiveness of a nurse-led support and nicotine replacement therapy (NRT) prescription during smokers' hospital stay in four departments of a university hospital on one-month abstinence after discharge with a follow-up of quit attempts at 3 and 6 months. This is a stepped-wedge cluster trial, including four hospital departments. Inpatients who smoke in the experimental group will receive structured counseling and NRT prescribed by trained nurses in smoking cessation before discharge, while smokers in the control group receive standard care. The primary outcome is one-month abstinence post-discharge confirmed biochemically. Secondary outcomes, assessed at 1, 3, and 6 months post-discharge, include: abstinence, mean number of cigarettes smoked daily, quality of life scale, anxiety and depression symptoms score, addiction center use, and prescribed NRT during hospitalization and at discharge. Nurse job satisfaction will be measured at the beginning and at the end of the study. Statistical analyses will compare intervention and control groups using models appropriate for the stepped-wedge cluster randomized design (two-sided α = 0.05). Based on an expected 1-month abstinence rate of 15% in the control group and 30% in the intervention group, with 80% power, an intraclass correlation coefficient of 0.30, and 5% loss to follow-up, a total sample size of 442 participants is required. All data collected about the study participants will be anonymized. Results will be communicated to participants, hospital departments' staff and other relevant groups without any restrictions. The study is registered on the official website of ClinicalTrials.gov. NCT06789536.
SN - 2070-7266
SN - 1617-9625
ER -